5 Healthcare Companies Poised to Benefit Most Under a Second Trump Administration

As discussions grow around a possible second term for the Trump administration, many are speculating about which sectors could see the greatest impact. Healthcare companies, especially those aligned with policies favoring privatization, deregulation, and consumer-driven healthcare, are well-positioned to capitalize on potential changes. Here’s a look at five types of healthcare companies likely to benefit if the Trump administration returns to power.

Insurance Companies Offering Short-Term or Limited Benefit Plans

During his first term, Trump supported alternative insurance options, including short-term health plans, which are less regulated and generally offer limited benefits at lower costs. These plans attract consumers looking for basic coverage and reduced premiums, especially those who don’t qualify for subsidies under the ACA. Companies offering these short-term or limited coverage plans could thrive under a second Trump administration if there’s a renewed push to expand their availability.

• Examples: UnitedHealth Group, Cigna
• Reason for Potential Growth: Increased demand for affordable, flexible plans if ACA restrictions are further loosened.

Telemedicine and Digital Health Platforms

Telemedicine experienced explosive growth during the COVID-19 pandemic, driven by necessity and temporary regulatory relaxations. The Trump administration had shown interest in supporting telehealth to reduce barriers to care, particularly in rural areas. If telemedicine regulations are permanently eased and further incentivized, digital health companies stand to benefit significantly. Increased flexibility in telemedicine billing and expanded services could fuel revenue growth for these companies.

• Examples: Teladoc Health, Amwell
• Reason for Potential Growth: Expanded access to telehealth could be prioritized to reduce healthcare costs and increase convenience, particularly in underserved areas.

Pharmaceutical and Biotechnology Companies

A second Trump administration is expected to continue efforts to drive down drug prices, though with a focus on market competition rather than stringent regulation. Pharmaceutical companies producing essential generics or specialty medications may benefit if Trump prioritizes domestic drug production as part of his “America First” policy. Tax breaks and incentives for companies manufacturing drugs in the U.S. could reduce reliance on foreign suppliers and increase profit margins for domestic pharmaceutical and biotech firms.

• Examples: Pfizer, Merck, AbbVie
• Reason for Potential Growth: Companies positioned for domestic production may gain from incentives and policy shifts aimed at boosting the U.S. pharmaceutical manufacturing sector.

Medical Supply and Equipment Manufacturers

The pandemic underscored vulnerabilities in the U.S. supply chain for medical supplies and equipment. A second Trump administration might focus on bolstering domestic production of essential supplies, aligning with “America First” principles. Companies producing personal protective equipment (PPE), ventilators, and other critical medical supplies could benefit from increased federal support, subsidies, or procurement contracts designed to secure the national supply chain.

• Examples: 3M, Medtronic, Cardinal Health
• Reason for Potential Growth: Potential incentives for domestic production and stockpiling could lead to heightened demand and government contracts for medical supply manufacturers.

Companies Offering Consumer-Directed Healthcare Services

The Trump administration has promoted consumer-driven healthcare through Health Savings Accounts (HSAs) and other high-deductible health plans, encouraging individuals to manage their own healthcare expenses. Companies offering consumer-oriented services—like HSAs, health savings tools, and price comparison platforms—are likely to benefit if these initiatives expand further. Additionally, as transparency in healthcare pricing becomes a greater priority, companies that provide pricing data and cost-comparison tools for consumers could see increased demand.

• Examples: HealthEquity, GoodRx
• Reason for Potential Growth: An emphasis on consumer-directed healthcare and price transparency could drive demand for platforms and tools that empower patients to make cost-effective healthcare choices.

Conclusion

As we anticipate possible healthcare policy shifts under a second Trump administration, companies operating within areas such as telemedicine, domestic manufacturing, and consumer-driven healthcare stand to benefit most. By focusing on privatization, deregulation, and supply chain security, the administration could create opportunities for growth in specific healthcare sectors. However, it’s important to remember that policy directions can change quickly and the healthcare landscape is influenced by a wide array of factors.

Curious about the potential impact on your healthcare or investment options? Or have questions about how these shifts could reshape the industry? Share your thoughts and questions in the comments below—let’s explore the future of healthcare together!